A phase I study of HYB2055 in patients (pts) with advanced solid malignancies

被引：0
|
作者：
Hwang, JJ
Park, S
Amin, A
Martin, RR
Sullivan, T
Burns, T
Agrawal, S
Waxdal, MJ
Malik, S
Marshall, JL
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20057 USA
[2] Hybridon Inc, Cambridge, MA USA
[3] Fast Syst, Gaithersburg, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3111
引用
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [1] A phase I study of a second-generation immunumodulatory oligonucleotide (HYB2055) in patients with advanced solid malignancies.
    Hwang, JJ
    Martin, R
    Fox-Sinclair, ES
    Bahrani, A
    Sullivan, T
    Park, S
    Agrawal, S
    Burns, T
    Waxdal, M
    Marshall, JL
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6230S
  • [2] Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors.
    Moore, DJ
    Hwang, J
    McGreivy, J
    Park, S
    Malik, S
    Martin, RR
    Sullivan, TM
    Agrawal, S
    Marshall, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 166S - 166S
  • [3] Phase I trial of SU014813 in patients (pts) with advanced solid malignancies
    Fiedler, W. M.
    Giaccone, G.
    Lasch, P.
    Van der Horst, I.
    Brega, N. M.
    Raber, S.
    Shalinsky, D.
    Ljubmir, V.
    Bokemeyer, C.
    Boven, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase I study of E7080 in patients (pts) with advanced malignancies
    Glen, H.
    Boss, D. R.
    Morrison, R.
    Roelvink, M.
    Wanders, J.
    Mazur, A.
    Gupta, A.
    Das, A.
    Evans, T. R.
    Schellens, J. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies
    Feinstein, T. M.
    Agrawal, S.
    Stoller, R. G.
    Egorin, M. J.
    Argiris, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A phase I Study of ecteinascidin 743(E) and capecitabine (C) in patients (pts) with advanced solid malignancies.
    Holden, SN
    Rivera, E
    Basche, M
    Gore, L
    Raj, SKS
    O'Bryant, CL
    Grolnic, S
    Hunt, J
    Brillhart, B
    Van de Velde, H
    Roberts, D
    Rodgers, J
    Eckhardt, SG
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6080S - 6080S
  • [7] A phase I combination study of irofulven (IROF) and gemcitabine (GEM) in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Gore, L
    Long, M
    Gustafson, D
    Eppers, S
    Basche, M
    Rothenberg, M
    Weems, G
    Shah, A
    Herdrich, L
    Eckhardt, SG
    Berlin, J
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9120S
  • [8] A phase I study of tinostamustine in patients (pts) with advanced solid tumours
    Mita, A.
    Loeffler, M.
    Bui, N.
    Remmy, D.
    Mehrling, T.
    Mita, M.
    Rimel, B. J.
    Natale, R. B.
    Kummar, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 177 - +
  • [9] Phase I trial of cetuximab (C) and dasatinib (D) in patients (pts) with advanced solid malignancies
    Esteve, F. R.
    Stoller, R. G.
    Josephson, A.
    Grandis, J. R.
    Egorin, M. J.
    Argiris, A. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A phase I study of brostallicin (B) combined with either bevacizumab (BV) or irinotecan (I) in patients (pts) with advanced solid malignancies
    MacArthur, R. B.
    Singer, J.
    Becerra, C.
    Weitman, S.
    Von Hoff, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345